Back to Headlines
Health
Apr 23, 2026
Analyzed by Glm 4.7 Flash

The Fallout of Theramex's Regulatory Collapse: A Crisis in HRT Safety

AI Summary
Major HRT producer Theramex has been censured by the UK regulator for systemic safety failures, including outdated prescribing information and missed pregnancy warnings, forcing the company to exit the self-regulatory framework and face scrutiny from the MHRA.

The Fallout of Theramex's Regulatory Collapse

One of the UK's largest producers of hormone replacement therapy (HRT) has been publicly reprimanded by the Prescription Medicines Code of Practice Authority (PMCPA) for "systemic failures" that directly jeopardized patient safety. The case against Theramex, the maker of popular drugs Evorel and Intrarosa, highlights a critical breakdown in compliance standards that regulators say has eroded trust in the pharmaceutical industry.

Systemic Failures in HRT Safety Protocols

The PMCPA found that Theramex breached the Association of the British Pharmaceutical Industry (ABPI) code of practice 21 times. These failures were not isolated incidents but a pattern of negligence that included:

  • Failing to update crucial prescribing information for years, including for Evorel patches.
  • Not clearly warning that certain drugs, such as Yselty (linzagolix), must not be used during pregnancy.
  • Ignoring internal whistleblower concerns regarding incomplete side-effect data.

The Scale of Prescribed Risk

The impact of these failures is magnified by the sheer volume of prescriptions. Evorel patches, which contain estradiol, are among the most prescribed forms of transdermal HRT, with 250,000+ items issued in the last financial year. Overall, nearly 10 million items of estradiol were prescribed in the 2024/25 financial year, meaning thousands of patients may have been exposed to incomplete or outdated safety data.

The Erosion of Self-Regulation

The decision by Theramex to leave the PMCPA's jurisdiction in January 2026 has sparked a debate on the efficacy of self-regulation. The PMCPA condemned the move, stating it inevitably delayed oversight. However, the Medicines and Healthcare products Regulatory Agency (MHRA) has stepped in, asserting that leaving the self-regulatory framework does not grant immunity. Dr Amit Aggarwal noted that Theramex has "brought discredit upon" the industry, signaling a potential shift toward stricter, government-led enforcement.

Future Scrutiny and Industry Reform

Looking ahead, the Theramex case is likely to trigger a comprehensive review of compliance frameworks across the pharmaceutical industry. With the MHRA retaining full legal powers to investigate and prosecute criminal offences, companies can no longer rely on voluntary self-regulation to shield them from liability. The industry faces a critical juncture where patient safety must take precedence over administrative efficiency.